Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of \$50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is <u>only effective</u> for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at ecor@mgh.harvard.edu

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

Process

Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to ecor@mgh.harvard.edu. In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

- 1. Name of the Principal Investigator with appropriate contact information
- 2. A descriptive title of the potential application
- 3. Brief description of the project
- 4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at ecor@mgh.harvard.edu.

CURRENT OPPORTUNITIES

1. Neurosurgeon Research Career Development Program (NRCDP) (K12 Independent Clinical Trial Not Allowed) – NEW!

https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-019.html

MGH LOI Deadline: 10/22/21 NIH Application Deadline: 12/15/21

The purpose of this funding opportunity announcement (FOA) is to invite applications to continue support for the Neurosurgeon Research Career Development Program (NRCDP), a national program of mentored research career development for junior neurosurgeon faculty at institutions nationwide that support neurosurgical research. The goal of the program is to expand the cadre of neurosurgeon investigators trained to conduct high-quality, impactful research into neurological disorders, making use of their neurosurgical training.

2. Responsive Grants, Retirement Research Foundation (RRF)

https://www.rrf.org/apply-for-a-grant/

MGH LOI Deadline: 11/01/21 Sponsor LOI Deadline: 11/15/21

Sponsor Application Deadline (Invited): 2/1/22

RRF Foundation for Aging focuses on improving the quality of life for older people. In an effort to strengthen the Foundation's impact, RRF has established Priority Areas. These Priority Areas are specific topics in aging that will be given higher priority within the Foundation's grantmaking program.

Types of Grants

- 1. Advocacy: Achieve enduring social change around issues that affect older Americans
- 2. **Direct Service:** Improve availability and quality of community-based services and supports in seven states
- 3. Research: Seek causes and solutions to significant problems for older persons
- 4. **Professional Education & Training:** Increase the competency of professionals and paraprofessionals who serve older people
- 5. **Organizational Capacity Building:** Improve management and governance of non-profit organizations
- 3. NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genetic Research Centers (GRCs) (U01 Clinical Trial Optional)

https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-022.html

MGH LOI Deadline: 11/02/21 NIH LOI Deadline: 11/21/21

NIH Application Deadline: 12/21/21

The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) was established in July 2002 for the purpose of identifying genetic variation predisposing to Inflammatory Bowel Disease (IBD). Since its establishment and in collaboration with the International IBD Genetics Consortium, the NIDDK IBDGC has identified over 250 IBD susceptibility loci. However, for the great majority of these loci, the specific causal variants and effector genes have not yet been identified, and the biological mechanisms through which these variants influence IBD pathophysiology remain to be elucidated. The purpose of this Funding Opportunity Announcement (FOA) is to renew the IBDGC with a continued mission to characterize the genetic architecture of IBD phenotypes, particularly in populations currently underrepresented in IBD genomic studies, and to elucidate the biological mechanisms by which genetic variants influence IBD pathophysiology, phenotypes and clinical course. The Genetic Research Centers (GRCs) of the IBDGC will serve as sites for enrollment of IBD patients, relatives and healthy controls, for laboratory-based studies on biological samples obtained from these subjects, and for mechanistic studies of the risk variants identified, and of the genes, proteins and pathways they impact.

4. Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed)

https://grants.nih.gov/grants/guide/pa-files/PAR-21-337.html

MGH LOI Deadline: 11/16/21 NIH Application Deadline: 1/26/21

The National Center for Advancing Translational Sciences (NCATS) will award Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Institutional Research Training Grants for the Clinical and Translational Science Awards (CTSA) Program (T32) to eligible institutions to enhance predoctoral research training of individuals seeking a PhD or an equivalent research health professional degree and help ensure a heterogenous pool of clinical and translational scientist trainees who are equipped with the knowledge, skills and abilities to advance diagnostics, therapeutics, clinical interventions, and behavioral modifications aimed at improving health.

Applicants interested in providing short-term research experiences to health professional participants must apply to the companion NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Programs (R25) (PAR-21-339). A short-term research experience is one where the participant is full-time (40 hours per week) for a period of 10 to 15 weeks, or as specified by the sponsoring institution in accordance with its own policies.

The proposed institutional research training program may complement other ongoing research training and career development programs at the applicant institution but must be clearly distinct from related programs currently receiving Federal support.

This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial on which the PI is a mentor or co-mentor. NIH strongly supports training towards a career in clinically relevant research and so gaining experience in clinical trials under the guidance of a mentor or co-mentor is encouraged.

NIH requires each applicant to submit a subsequent UM1 application (PAR-21-293: Clinical and Translational Science Award) concurrently with the T32 application. MGH is limited to one T32 application per institution. If an applicant has not submitted a companion UM1, the T32 will not be reviewed.

When submitting your internal LOI to ECOR, please include the title of you UM1 application.

 Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed)

https://grants.nih.gov/grants/guide/pa-files/PAR-21-338.html

MGH LOI Deadline: 11/16/21 NIH Application Deadline: 1/26/21

The National Center for Advancing Translational Sciences (NCATS) will award Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Institutional Research Training Grants for the Clinical and Translational Science Awards (CTSA) Program (T32) to eligible institutions to enhance postdoctoral research training of individuals with doctoral degrees (these include, but are not limited to, the following: D.M.D., DC, DO, DVM., OD, DPM, ScD, EngD, DrPH, DNSc, DPT, PharmD, ND [Doctor of Naturopathy], DSW, PsyD, as well as a doctoral degree in nursing research) and help ensure a

heterogenous pool of clinical and translational scientists trainees are equipped with the knowledge, skills and abilities to advance diagnostics, therapeutics, clinical interventions, and behavioral modifications that improve health.

NCATS will not accept applications proposing combined predoctoral and postdoctoral training under this FOA. Applications proposing predoctoral research training should apply to the Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Institutional Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (PAR-21-337).

The proposed institutional research training program may complement other ongoing research training and career development programs at the applicant institution, but must be clearly distinct from related programs currently receiving Federal support.

This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial on which the PI is a mentor or co-mentor.

NIH requires each applicant to submit a subsequent UM1 application (PAR-21-293: Clinical and Translational Science Award) concurrently with the T32 application. MGH is limited to one T32 application per institution. If an applicant has not submitted a companion UM1, the T32 will not be reviewed.

When submitting your internal LOI to ECOR, please include the title of you UM1 application.

6. Genomic Curriculum Development for Medical Students (R25 Clinical Trial Not Allowed) – NEW! https://grants.nih.gov/grants/guide/pa-files/PAR-21-312.html

MGH LOI Deadline: 12/06/21 NIH Application Deadline: 1/25/21

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on *Curriculum Development*. This NHGRI R25 program offers to support the development of curricula for Master of Science (M.S.) degree programs in genomics, genomic medicine and/or genomic informatics for medical students. Specifically, this FOA will support the development of curriculum designed to be freely available, at no cost to the broader community to enhance training in genomics for medical students.

7. SUNBEAM – Analysis and Bioinformatics Center (ABC) (UM1 Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-060.html

MGH LOI Deadline: 12/08/21 NIH LOI Deadline: 1/15/22

NIH Application Deadline: 2/15/21

The purpose of the SUNBEAM - Analysis and Bioinformatics Center (SUNBEAM-ABC) is to establish a mechanistic omics center to support the birth cohort study Systems Biology of Early Atopy (SUNBEAM).

The center will assay biologic samples collected within the SUNBEAM cohort using omics and systems biology approaches to identify determinants of atopic disease, focusing on food allergy and atopic dermatitis (AD) in newborns, infants, and very young children. SUNBEAM-ABC will support the SUNBEAM birth cohort study by providing analytic infrastructure for a comprehensive understanding of molecular and cellular pathways that contribute to atopic disease development and to identify early predictive biomarkers.